Raynaud's phenomenon. Case report
DOI:
https://doi.org/10.18041/2390-0512/bioc..1.2452Keywords:
vascular endothelium, cyanosis, vasoconstrictionAbstract
We present the case of a female patient of 41 years of age, with a history of rheumatoid arthritis, discoid lupus, iron deficiency anemia, under treatment with chloroquine 150 mg day, prednisolone 40 mg day, folic acid 1 mg day; who enters for distal cyanosis of 3 and 4 phalanxes right hand after exposure to cold. Paraclinics show leukocytosis with neutrophilia, hypochromic microcytic anemia, thrombocytes, c-reactive protein, anti-turbulent antibody positive, complement, anti-DNA, anti-cardiolipin antibodies, negative anti-phospholipid antibodies, radiography of hands with peri-articular osteopenia, hydration, corticoids, cycle of cyclophosphamide, presenting later clinical improvement and proceeded to give the medical discharge to perform second cycle a month.
Downloads
References
2- Nitsche A. Raynaud, úlceras digitales y calcinosis en esclerodermia. Reumatología Clínica. 2012; 8(5):270–277.
3- Carrera JM, Zamora Ramírez R y García Porrúa C. El fenómeno de Raynaud. FMC. 2012;19(6):347-52
4- Leppert J, Ringqvist A, Karlberg B, Ringqvist I. Whole-body cooling increases plasma endothelin-1 levels in women with primary Raynaud’s phenomenon. Clin Physiol. 1998; 18:420-5.
5- Jinnin M, Makino T, Kajihara I, Honda N, Makino K, Ogata A, et al. Serum levels of soluble vascular endothelial growth factor receptor-2 in patients with systemic sclerosis. Br J Dermatol. 2010; 162:751-8.
6- Tolosa Vilella C, Simeón Aznar C, Gabarró J. El fenómeno de Raynaud. Med Clin (Barc). 2009; 132(18):712–718
7- Wigley FM. Clinical manifestations and diagnosis of the Raynaud phenomenon [Internet]. 2012 [citado 2014 septiembre 15]. Disponible en: http://goo.gl/lWd7pn.
8- Kinney E, Nicholas G, Gallo J, Pontoriero C, Zelis R. The treatment of severe Raynaud’s phenomenon with verapamil. J Clin Pharmacol. 1982; 22:74-6
9- Postlethwaite A, Chiang T. Platelet contributions to the pathogenesis of systemic sclerosis. Curr Opin Rheumatol. 2007;19:574-9
10- Denton C, Howell K, Stratton R, Black C. Long-term low molecular weight heparin therapy for severe Raynaud’s phenomenon: a pilot study. Clin Exp Rheumatol. 2000; 18:499-502.
11- Brueckner C, Becker M, Kroencke T, Huscher D, Scherer H, Worm M, et al. Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study. Ann Rheum Dis. 2010; 69:1475-8.
12- Herrick AL. Contemporary management of Raynaud s phenomenon and digital ischaemic complications. Curr Opin Rheumatol. 2011; 23:555–61.
